Saamya Biotech (India) Ltd vs CIPLA LTD

A side-by-side comparison of Saamya Biotech (India) Ltd (532905) and CIPLA LTD (CIPLA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, CIPLA LTD leads 532905 vs CIPLA on 9 of 14 metrics (1 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

0.00
P/E ratio
29.54
0.00
P/B ratio
3.42
0.00%
Dividend yield
0.90%
₹-0.18
EPS
₹48.02

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

-1.93%
Return on equity
11.60%
-3.29%
Return on capital
15.00%
-0.86%
EBITDA margin
21.00%
-2.91%
Net margin
13.71%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

71.84%
Revenue CAGR (3Y)
7.37%
Profit CAGR (3Y)
10.88%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹0 Cr
Market cap
₹1.15L Cr
₹15 Cr
Revenue
₹28,163 Cr
₹-0 Cr
Net profit
₹3,862 Cr
0.00
Debt / equity
0.02
Saamya Biotech (India) Ltd
  • ["Company has low interest coverage ratio.", "Company has a low return on equity of -1.27% over last 3 years.", "Company has high debtors of 1,211 days."]
CIPLA LTD
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 25.7%"]
  • ["The company has delivered a poor sales growth of 8.01% over past five years.", "Promoter holding has decreased over last 3 years: -4.34%"]
Saamya Biotech (India) Ltd full analysis CIPLA LTD full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.

Saamya Biotech (India) Ltd vs CIPLA LTD: Share Price, Valuation & Which to Buy | DocStoX